The Uterine Adenosarcoma in a Young Woman Treated by TAH/BOS and Combined Adjuvant Therapy: A Case Report
-
Soodabeh Shahidsales
,
Marjaneh Farazestanian
,
Noorieh Sharifi‐Sistani
,
Sara Rasta
,
Seyed Alireza Javadinia
Abstract
We aimed to report a woman suffering from uterine adenosarcoma in perimenopause period .The patient had undergone total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) and also received adjuvant chemotherapy and radiotherapy. Moreover, she was reported as disease free with no evidence of recurrence or metastasis despite existence of numerous risk factors such as deep myometrial invasion as well as sarcomatous overgrowth after one year of follow-up. The results obtained about this patient could highlight the role of adjuvant therapy in terms of managing treatments for patients suffering from MASO especially in the presence of deep myometrial invasion and an advanced stage.
1. Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(9 Suppl 3):S78-82. doi:10.1097/igc.0000000000000239.
2. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Human pathology. 2009;40(11):1571-85. doi:10.1016/j.humpath.2009.03.018.
3. Hensley ML. Uterine sarcomas: histology and its implications on therapy. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2012:356-61. doi:10.14694/EdBook_AM.2012.32.356.
4. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecologic oncology. 2014;135(3):455-61. doi:10.1016/j.ygyno.2014.10.022.
5. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1992;11(2):75-88.
6. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305-8. doi:10.1016/j.ygyno.2010.07.001.
7. Goh C, Lin XH, Chin PS, Lim YK. Uterine preservation in a young patient with adenosarcoma of the uterus - Case report and review of literature. Gynecologic oncology reports. 2018;25:27-9. doi:10.1016/j.gore.2018.05.002.
8. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol. 2001;83(1):89-94. doi:10.1006/gyno.2001.6334.
9. Farhat MH, Hobeika EM, Moumneh G, Nassar AH. Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report. Journal of Medical Case Reports. 2007;1(1):103. doi:10.1186/1752-1947-1-103.
10. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncology reports. 1998;5(4):939-44.
11. Lee SJ, Bae JH, Kim DC, Park JS, Namkoong SE. Oral progesterone treatment in a young woman with mullerian adenosarcoma whose ovary was preserved: a case report. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(7):1222-4.
12. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer. 1981;48(2):354-66.
13. Tanner EJ, Toussaint T, Leitao MM, Jr., Hensley ML, Soslow RA, Gardner GJ et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129(1):140-4. doi:10.1016/j.ygyno.2012.12.036.
2. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Human pathology. 2009;40(11):1571-85. doi:10.1016/j.humpath.2009.03.018.
3. Hensley ML. Uterine sarcomas: histology and its implications on therapy. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2012:356-61. doi:10.14694/EdBook_AM.2012.32.356.
4. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecologic oncology. 2014;135(3):455-61. doi:10.1016/j.ygyno.2014.10.022.
5. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1992;11(2):75-88.
6. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305-8. doi:10.1016/j.ygyno.2010.07.001.
7. Goh C, Lin XH, Chin PS, Lim YK. Uterine preservation in a young patient with adenosarcoma of the uterus - Case report and review of literature. Gynecologic oncology reports. 2018;25:27-9. doi:10.1016/j.gore.2018.05.002.
8. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol. 2001;83(1):89-94. doi:10.1006/gyno.2001.6334.
9. Farhat MH, Hobeika EM, Moumneh G, Nassar AH. Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report. Journal of Medical Case Reports. 2007;1(1):103. doi:10.1186/1752-1947-1-103.
10. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncology reports. 1998;5(4):939-44.
11. Lee SJ, Bae JH, Kim DC, Park JS, Namkoong SE. Oral progesterone treatment in a young woman with mullerian adenosarcoma whose ovary was preserved: a case report. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(7):1222-4.
12. Zaloudek CJ, Norris HJ. Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer. 1981;48(2):354-66.
13. Tanner EJ, Toussaint T, Leitao MM, Jr., Hensley ML, Soslow RA, Gardner GJ et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129(1):140-4. doi:10.1016/j.ygyno.2012.12.036.
| Files | ||
| Issue | Vol 58, No 3 (2020) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/acta.v58i3.3779 | |
| Keywords | ||
| uterine adenosarcoma treatment adjuvant therapy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Shahidsales S, Farazestanian M, Sharifi‐Sistani N, Rasta S, Javadinia SA. The Uterine Adenosarcoma in a Young Woman Treated by TAH/BOS and Combined Adjuvant Therapy: A Case Report. Acta Med Iran. 2020;58(3):138-141.
